214 related articles for article (PubMed ID: 35076580)
1. RhoA, Claudin 18, and c-MET in Gastric Cancer: Clinicopathological Characteristics and Prognostic Significance in Curative Resected Patients.
Pereira MA; Ramos MFKP; Dias AR; Cardili L; Ribeiro RRE; de Castria TB; Zilberstein B; Nahas SC; Ribeiro U; de Mello ES
Med Sci (Basel); 2021 Dec; 10(1):. PubMed ID: 35076580
[No Abstract] [Full Text] [Related]
2. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer.
Wang C; Wang Y; Chen J; Wang Y; Pang C; Liang C; Yuan L; Ma Y
BMC Gastroenterol; 2023 Aug; 23(1):283. PubMed ID: 37582713
[TBL] [Abstract][Full Text] [Related]
3. Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study.
Dottermusch M; Krüger S; Behrens HM; Halske C; Röcken C
Virchows Arch; 2019 Nov; 475(5):563-571. PubMed ID: 31332522
[TBL] [Abstract][Full Text] [Related]
4. The Correlation Between RhoA Expression and Clinicopathological Characteristics in Gastric Cancer Patients After Curative Surgery.
Huang KH; Lan YT; Chen MH; Chao Y; Lo SS; Li AF; Wu CW; Chiou SH; Yang MH; Shyr YM; Fang WL
World J Surg; 2015 Sep; 39(9):2289-99. PubMed ID: 26013205
[TBL] [Abstract][Full Text] [Related]
5. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer.
Jia K; Chen Y; Sun Y; Hu Y; Jiao L; Ma J; Yuan J; Qi C; Li Y; Gong J; Gao J; Zhang X; Li J; Zhang C; Shen L
BMC Med; 2022 Jul; 20(1):223. PubMed ID: 35811317
[TBL] [Abstract][Full Text] [Related]
6. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
7. Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: A literature review with expert opinion.
Angerilli V; Ghelardi F; Nappo F; Grillo F; Parente P; Lonardi S; Luchini C; Pietrantonio F; Ugolini C; Vanoli A; Fassan M
Pathol Res Pract; 2024 Feb; 254():155145. PubMed ID: 38277741
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: A retrospective study.
Qi C; Chong X; Zhou T; Ma M; Gong J; Zhang M; Li J; Xiao J; Peng X; Liu Z; Li Z; Shen L; Zhang X
Chin J Cancer Res; 2024 Feb; 36(1):78-89. PubMed ID: 38455365
[TBL] [Abstract][Full Text] [Related]
9. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer.
Pereira MA; Ramos MFKP; Dias AR; Ribeiro R; Cardili L; Zilberstein B; Cecconello I; Ribeiro U; de Mello ES; de Castria TB
Virchows Arch; 2021 Jun; 478(6):1039-1048. PubMed ID: 33098489
[TBL] [Abstract][Full Text] [Related]
10. Correlation of Claudin18.2 expression with clinicopathological characteristics and prognosis in gastric cancer.
Tao D; Guan B; Li Z; Jiao M; Zhou C; Li H
Pathol Res Pract; 2023 Aug; 248():154699. PubMed ID: 37487317
[TBL] [Abstract][Full Text] [Related]
11. Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy.
Iwaya M; Hayashi H; Nakajima T; Matsuda K; Kinugawa Y; Tobe Y; Tateishi Y; Iwaya Y; Uehara T; Ota H
Histopathology; 2021 Aug; 79(2):227-237. PubMed ID: 33590909
[TBL] [Abstract][Full Text] [Related]
12. miR-1303 targets claudin-18 gene to modulate proliferation and invasion of gastric cancer cells.
Zhang SJ; Feng JF; Wang L; Guo W; Du YW; Ming L; Zhao GQ
Dig Dis Sci; 2014 Aug; 59(8):1754-63. PubMed ID: 24647998
[TBL] [Abstract][Full Text] [Related]
13. c-Met-dependent phosphorylation of RhoA plays a key role in gastric cancer tumorigenesis.
Liu J; Li S; Chen S; Chen S; Geng Q; Xu D
J Pathol; 2019 Sep; 249(1):126-136. PubMed ID: 31056743
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer.
Kubota Y; Kawazoe A; Mishima S; Nakamura Y; Kotani D; Kuboki Y; Bando H; Kojima T; Doi T; Yoshino T; Kuwata T; Shitara K
ESMO Open; 2023 Feb; 8(1):100762. PubMed ID: 36610262
[TBL] [Abstract][Full Text] [Related]
15. The Prognostic Significance of c-MET and EGFR Overexpression in Resected Gastric Adenocarcinomas.
Paliga A; Marginean H; Tessier-Cloutier B; Purgina B; Jonker D; Marginean EC
Am J Clin Oncol; 2017 Dec; 40(6):543-551. PubMed ID: 26125303
[TBL] [Abstract][Full Text] [Related]
16. Significance of tumor heterogeneity of p-Smad2 and c-Met in HER2-positive gastric carcinoma with lymph node metastasis.
Tsujio G; Maruo K; Yamamoto Y; Sera T; Sugimoto A; Kasashima H; Miki Y; Yoshii M; Tamura T; Toyokawa T; Tanaka H; Muguruma K; Ohira M; Yashiro M
BMC Cancer; 2022 Jun; 22(1):598. PubMed ID: 35650563
[TBL] [Abstract][Full Text] [Related]
17. Gastric cancer molecular classification based on immunohistochemistry and in situ hybridization: Analysis in western patients after curative-intent surgery.
Ramos MFKP; Pereira MA; de Mello ES; Cirqueira CDS; Zilberstein B; Alves VAF; Ribeiro-Junior U; Cecconello I
World J Clin Oncol; 2021 Aug; 12(8):688-701. PubMed ID: 34513602
[TBL] [Abstract][Full Text] [Related]
18. Decreased expression of claudin-18.2 in alpha-fetoprotein-producing gastric cancer compared to conventional gastric cancer.
Weng W; Zhang M; Ni S; Tan C; Xu M; Wang X; Sun H; Wang L; Huang D; Sheng W
J Gastrointest Oncol; 2022 Jun; 13(3):1035-1045. PubMed ID: 35837176
[TBL] [Abstract][Full Text] [Related]
19. Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer.
Baek JH; Park DJ; Kim GY; Cheon J; Kang BW; Cha HJ; Kim JG
Anticancer Res; 2019 Dec; 39(12):6973-6979. PubMed ID: 31810969
[TBL] [Abstract][Full Text] [Related]
20. The expression of Claudin-4 in gastric cancer tissue: A single center experience.
Moris D; Schizas D; Michalinos A; Kanavidis P; Dimitrokallis N; Alexandrou A; Misiakos E; Liakakos T
J BUON; 2017; 22(2):403-409. PubMed ID: 28534362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
